References

1. Smith AL, Ramsey B. Aerosol administration of antibiotics. Respiration 62(suppl 1):19-24, 1995.

2. Gonda I. The ascent of pulmonary drug delivery. J Pharm Sci 89:940-945, 2000.

3. Fiel SB. Aerosolized antibiotic treatment for cystic fibrosis. RT, J Respir Care Prac 11:79, 1998.

4. Smaldone GC, Palmer LB. Aerosolized antibiotics: current and future. Respir Care 45(6):667-675, 2000.

5. O'Riordan TG. Inhaled antimicrobial therapy: from cystic fibrosis to the flu. Respir Care 45(7):836-845, 2000.

6. Prober CG, Walson PD, Jones J. Technical report: precautions regarding the use of aerosolized antibiotics. Pediatrics 106(6):e89, 2000.

7. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasilkev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 340:23-30, 1999.

8. Suarez S, Hickey AJ. Drug properties affecting aerosol behavior. Respir Care 45(6):652-666, 2000.

9. Clay MM, Pavia D, Newman SP, Clarke SW. Factors influencing the size distribution of aerosols from jet nebulizers. Thorax 38:755-759, 1983.

10. Touw DJ, Jacobs FA, Brimicome RW, Heijerman HG, Bakker W, Briemer DD. Pharmacokinetics of aerolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 41:184-187, 1997.

11. Cystic Fibrosis Foundation. Patient Registry 1998 annual data report. Bethesda, MD: The Foundation, 1999.

12. Burns JL, Ramsey BW, Smith AL. Clinical manifestation and treatment of pulmonary infections in cystic fibrosis. Adv Pediatr Infect Dis 8:53-66, 1993.

13. Borsje P, DeJongste JC, Mouton JW, Tiddens HAWM. Aerosol therapy in cystic fibrosis: a survey of 54 CF centers. Pediatr Pulmonol 30:368-376, 2000.

14. Campbell PW, Saiman L. Use of aerolized antibiotics in patients with cystic fibrosis. Chest 116:775-788, 1999.

15. Stephens D, Garey N, Isles A. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis J 2:209-211, 1983.

16. Schaad RB, Wedgwood-Kruko J, Suter S. Efficacy of inhaled as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 111:599-665, 1987.

17. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment. Lancet 338:725-726, 1991.

18. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 23:330-335, 1997.

19. Vasquez C, Municio M, Corera M. Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Acta Paediatr 82:308-309, 1993.

20. Heinzl B, Eber E, Oberwaldner B, Haas G, Zach MS. Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr Pulmonol 33:32-37, 2002.

21. Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 2:1137-1139, 1981.

22. Stead RJ, Hodson ME, Batten JC. Inhaled certazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 81:273-279, 1987.

23. Mukhopadhyay S, Singh M, Cater JI, Ogston S, Franklin M, Olver RE. Nebulized antipseudomonas antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 51:364-368, 1996.

24. Littlewood JM, Miller MG, Ghoneim AT. Nebulized colomycin for use in early Pseudomonas colonization in cystic fibrosis. Lancet 1:865, 1985.

25. Jensen T, Pedersen SS, Garne S. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 19:831-838, 1987.

26. Bauldoff GS, Nunley DR, Manzetti JD. Use of aerosolized colistin sodium in cystic fibrosis awaiting lung transplantation. Transplantation 64:748-752, 1997.

27. Ramsey BW, Dorkin HL, Eisenberg JD. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 328:1740-1746, 1993.

28. Moss RB. Long-term benefit of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 121:55-63, 2002.

29. Nikolaizik WH, Jenni-Galovic V, Schoni MH. Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis. Eur J Pediatr 155:608-611, 1996.

30. Melani AS, Di Gregorio A. Acute respiratory failure due to gentamicin aerosolization. Monaldi Arch Chest Dis 53:274-276, 1998.

31. Steinkamp G, Trummler B, Gappa M. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 6:91-98, 1989.

32. Smith AL, Ramsey BW, Hedges DL. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 7:265-271, 1989.

33. Burns JL, Ramsey BW, Smith AL. Clinical manifestations and treatment of pulmonary ifections in cystic fibrosis. Adv Pediatr Infect Dis 8:53-66, 1993.

34. MacDonald NE. Pseudomonas aeruginosa and cystic fibrosis: antibiotic therapy and the science behind the magic. Can J Infect Dis 335-342, 1997.

35. Saiman L, Mehar F, Niu WW. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 23:532-537, 1996.

36. Burns JL, Van Dalfsen JM, Shawar RM. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179:1190-1196, 1999.

37. Coats AL, MacNeish CF, Meisner D. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest 111:1206-1212, 1997.

38. Iliwite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Resp Dis 136:1445-1449, 1987.

39. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, Ramsey RW. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 111:955-962, 1997.

40. Le Brun PPH, De Boer AH, Mannes GPM, de Fraiture DMI, Brimicombe RW, Touw DJ, Vinks AA, Frijlink HW, Heijerman GM. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry power formulation: a feasibility study in healthy volunteers and patients. Eur J Pharmaceut Biopharmaceut 54:25-32, 2002.

Dealing With Asthma Naturally

Dealing With Asthma Naturally

Do You Suffer From ASTHMA Chronic asthma is a paralyzing, suffocating and socially isolating condition that can cause anxiety that can trigger even more attacks. Before you know it you are caught in a vicious cycle Put an end to the dependence on inhalers, buying expensive prescription drugs and avoidance of allergenic situations and animals. Get control of your life again and Deal With Asthma Naturally

Get My Free Ebook


Post a comment